Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

 

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an ARCH scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

 

The CIHR grant entitled "A Multifaceted Function for Dipeptidase-1 in Kidney Injury" was awarded to a research team at the University of Calgary led Dr. Daniel Muruve. Dr. Muruve is also the Chief Science Officer of Arch. The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD.

 

Quote from Dr. Daniel Muruve:

 

"The cause of kidney disease is generally unknown and as a result, there are currently few treatments for acute kidney injury (AKI) or CKD. The only treatment for kidney failure, at present, is life support using dialysis or kidney transplantation. A better approach is to find new treatments for AKI and CKD that prevent kidney failure altogether. We have strong evidence that inflammation and DPEP-1 play very important roles in kidney injury and disease. We plan to study exactly how DPEP-1 contributes to kidney disease, including CKD and how to best target its function therapeutically."

 

  About DPEP-1 and Organ Inflammation  

 

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In the publication, the enzyme DPEP-1 was identified, for the first time, as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. Their findings established DPEP-1 as a novel therapeutic target for diseases of these organs where inflammation plays a major role and demonstrated that DPEP-1 is the target of the Company's lead drug candidate, LSALT Peptide. The publication can be found at the following link:

 

  "Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver"  

 

Subsequently in 2022, Dr. Muruve and his team explained in a publication in Science Advances how DPEP-1 regulates inflammation in the kidney. The publication can be found at the following link:

 

   "Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury"   

 

  About Arch Biopartners  

 

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

 

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

 

The Company has 62,398,825 common shares outstanding.

 

  Forward-Looking Statements  

 

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements, except as required by law.

 

  The science and medical contents of this release have been approved by the Company's Chief Science Officer  

 

  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release  

 
For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com
 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

ARCH
The Conversation (0)
Equity Metals Drilling Underway on the Silver Queen Ag-Au Property, British Columbia

Equity Metals Drilling Underway on the Silver Queen Ag-Au Property, British Columbia

Equity Metals Corporation (TSXV: EQTY) ("Equity" or the "Company") reports that drilling is underway on the 100% owned 18,871 ha Silver Queen Property, northern British Columbia. Four holes totaling 1,422 metres of the planned 18 hole, 6,000 metre 2025 drill program have been completed to date, with the current holes testing down-dip of higher-grade mineralized intercepts from the 2024 drilling (see Figure 2 and 2024 highlights below). Subsequent drilling will continue testing along strike, up to 400 metres laterally to the northwest. Drill core is being logged and sampled for analyses with assays anticipated in the coming weeks.

The 2025 drill program is a continuation of drilling completed in Q4/24, which successfully confirmed both the grade and tenor of mineralization beneath historical underground workings beyond the northwestern end of No. 3 resource blocks. Drilling at that time extended the projection of the No. 3 Vein for 400 metres strike-length and to over 250 metres depth below surface. Mineralization remains open both laterally and at depth, and expanding projections of that mineralization is the target of the current 2025 drill program on the property.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Finlay Minerals announces the commencement of the 2025 PIL & ATTY Property Exploration Programs

Finlay Minerals announces the commencement of the 2025 PIL & ATTY Property Exploration Programs

 
 

finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce the start of the 2025 exploration programs for its PIL and ATTY Properties within the Toodoggone Mining District of Northern British Columbia .  These programs are fully funded under the Earn-In Agreements with Freeport-McMoRan Mineral Properties Canada Inc. ("Freeport"). Under these agreements, Freeport can earn up to an 80% interest in each property by investing $35 million in exploration expenditures and making cash payments of $4.1 million over a period of six years. ( Reference #1 ).

 

The exploration programs at PIL and ATTY are designed to best outline and prioritize as many targets as possible for drill testing in 2026. The 2025 programs at both PIL and ATTY will consist of the following activities with Finlay acting as Operator:

 

 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Equity Metals Initiates Drilling on the Arlington Gold Property, British Columbia

Equity Metals Initiates Drilling on the Arlington Gold Property, British Columbia

Equity Metals Corporation (TSXV: EQTY) ("Equity" or the "Company") reports that drilling has commenced on the Arlington property, southern British Columbia.

Up to 3,000 metres of drilling will target three separate clusters of strongly anomalous Au-Ag-As-in-soil anomalies in the south Fresh Pots area (Figure 1) that have been enhanced by geophysical features identified in a recently completed DCIP geophysical survey. Additional surface sampling and mapping towards further drill target definition is also planned for the north Fresh Pots, Rona and other target areas on the property and will include initial targeting on several new claims that were staked earlier this year. Work will continue through the month of June and into the early part of July.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Equity Metals Corporation to Participate in THE Mining Investment Event, Canada's Only Tier I Global Mining Investment Conference

Equity Metals Corporation to Participate in THE Mining Investment Event, Canada's Only Tier I Global Mining Investment Conference

Equity Metals Corporation (TSXV: EQTY) (OTCQB: EQMEF), Equity Metals is exploring for SilverGold in Central British Columbia, is pleased to announce that it will be participating in THE Mining Investment Event, Canada's Only Tier 1 Global Mining Investment Conference©, taking place June 3-5, 2025, at the Quebec Convention Centre, Quebec City, Canada.

Equity Metals Corporation's management will be available to meet, and hold scheduled one-on-one investor meetings throughout the three-day conference.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×